Skip to main content

Advertisement

Table 4 Early evaluation of tumor response to sunitinib by RECIST 1.1 and Choi criteria

From: Early evaluation of sunitinib for the treatment of advanced gastroenteropancreatic neuroendocrine neoplasms via CT imaging: RECIST 1.1 or Choi Criteria?

No. of patient Change in tumor size (%) Change in tumor density (%) RECIST 1.1 response Choi response TTP (m)
1 −34 −15 PR PR 16.6
2 −42 −21 PR PR 6.4
3 −45 11 PR PR 18.5
4 −50 −54 PR PR 13.0
5 −15 3 SD PR 7.4
6 5 −15 SD PR 22.8
7 −6 −18 SD PR 20.5
8 −9 −34 SD PR 2.4
9 −3 −8 SD SD 10.8
10 5 −5 SD SD 15.1
11 4 −3 SD SD 5.9
12 3 −5 SD SD 12.6
13 11 5 SD PD 5.7
14 11 −1 PDa PD 1.4
15 27 9 PD PD 3.1
16 15 −4 PDa PD 2.3
17 24 1 PD PD 2.1
18 21 8 PD PD 2.5
  1. aThe Progressive Disease of RECIST version 1.1 was the result of new lesions at the first follow up by CT scan, rather than the increase of tumor size